Psychedelics
Transforming Psychiatry
American Psychiatric Association Publishing
Will be published approx. on 25. September 2026
Book
Paperback/Softback
978-1-61537-497-7 (ISBN)
Description
Few topics in psychiatry over the past few years have
generated as much curiosity and excitement among clinicians and laypeople as
the use of psychedelics. For mental health professionals, psychedelics offer
an opportunity to expand existing treatment options and to explore new ones
that have the potential to change neuroplasticity and neuroconnectivity. For
patients, they offer the hope of relief from illnesses that have not
responded adequately to traditional treatments.
When approaching the
use of psychedelics in treatment, it is important to separate science from
sensationalism. Expert-vetted and rigorously researched, Psychedelics:
Transforming Psychiatry delivers an authoritative review of the
current knowledge and evidence for the use of psychedelics in practice.
Organized into three parts, this volume covers
* The history of
psychedelic research and treatment, as well as the pharmacological and
neurobiological mechanisms that underpin how these substances work
*
Clinical applications for targeted illnesses that include mood disorders,
PTSD, OCD and anxiety disorders, and substance use disorders
*
Precautions and risks when using psychedelics, the role of psychotherapy
when leveraging these substances, and potential future uses
The
contributions from an international panel of recognized experts are enriched
throughout the text by key clinical takeaways, data tables, and extensive
references. This is a thoughtful and informative review of the current,
rapidly developing landscape surrounding psychedelics in medicine.
generated as much curiosity and excitement among clinicians and laypeople as
the use of psychedelics. For mental health professionals, psychedelics offer
an opportunity to expand existing treatment options and to explore new ones
that have the potential to change neuroplasticity and neuroconnectivity. For
patients, they offer the hope of relief from illnesses that have not
responded adequately to traditional treatments.
When approaching the
use of psychedelics in treatment, it is important to separate science from
sensationalism. Expert-vetted and rigorously researched, Psychedelics:
Transforming Psychiatry delivers an authoritative review of the
current knowledge and evidence for the use of psychedelics in practice.
Organized into three parts, this volume covers
* The history of
psychedelic research and treatment, as well as the pharmacological and
neurobiological mechanisms that underpin how these substances work
*
Clinical applications for targeted illnesses that include mood disorders,
PTSD, OCD and anxiety disorders, and substance use disorders
*
Precautions and risks when using psychedelics, the role of psychotherapy
when leveraging these substances, and potential future uses
The
contributions from an international panel of recognized experts are enriched
throughout the text by key clinical takeaways, data tables, and extensive
references. This is a thoughtful and informative review of the current,
rapidly developing landscape surrounding psychedelics in medicine.
More details
Language
English
Place of publication
VA
United States
Target group
Professional and scholarly
US School Grade: College Graduate Student and over
Product notice
Paperback (trade)
Illustrations
4 Halftones, black and white; 6 Line drawings, black and white; 13 Tables, unspecified
Dimensions
Height: 229 mm
Width: 152 mm
ISBN-13
978-1-61537-497-7 (9781615374977)
Copyright in bibliographic data is held by Nielsen Book Services Limited or its licensors: all rights reserved.
Schweitzer Classification
Persons
Scott T. Aaronson, M.D., is the Chief Science
Officer of the Institute for Advanced Diagnostics and Therapeutics at
Sheppard Pratt in Towson and an Adjunct Professor in the Department of
Psychiatry at the University of Maryland School of Medicine in Baltimore,
Maryland.
Albert Garcia-Romeu, Ph.D., is an Associate Professor
of Psychiatry and Behavioral Sciences at the Johns Hopkins School of
Medicine and the Associate Director of the Johns Hopkins Center for
Psychedelic and Consciousness Research in Baltimore,
Maryland.
Trisha Suppes, M.D., Ph.D., is Director of
Exploratory Therapeutics for Mood Disorders and Founder of the Bipolar and
Depression Research Program in the VA Palo Alto Health Care System in Palo
Alto, and Professor in the Department of Psychiatry and Behavioral Sciences
at Stanford University School of Medicine in Stanford, California.
Officer of the Institute for Advanced Diagnostics and Therapeutics at
Sheppard Pratt in Towson and an Adjunct Professor in the Department of
Psychiatry at the University of Maryland School of Medicine in Baltimore,
Maryland.
Albert Garcia-Romeu, Ph.D., is an Associate Professor
of Psychiatry and Behavioral Sciences at the Johns Hopkins School of
Medicine and the Associate Director of the Johns Hopkins Center for
Psychedelic and Consciousness Research in Baltimore,
Maryland.
Trisha Suppes, M.D., Ph.D., is Director of
Exploratory Therapeutics for Mood Disorders and Founder of the Bipolar and
Depression Research Program in the VA Palo Alto Health Care System in Palo
Alto, and Professor in the Department of Psychiatry and Behavioral Sciences
at Stanford University School of Medicine in Stanford, California.
Editor
Sheppard Pratt Health System
Associate ProfessorThe Johns Hopkins University School of Medicine
Content
Introduction
Part I: Context, History, and
Biological Underpinnings of Psychedelic Treatment
Chapter 1.
Psychedelic Research and Treatment: Brief History of a Key
Pioneers
Chapter 2. Pharmacological and Neurobiological Mechanisms of
Action of Psychedelic substances
Part II: Illness Targets for
Psychedelic Research and Treatment
Chapter 3. The Illness
Targets: Mood Disorders and Suicide
Chapter 4. MDMA-Assisted Therapy for
Treatment of PTSD
Chapter 5. Psychedelic Treatment of OCD and Anxiety
Disorders: Early Work
Chapter 6. Psychedelics in the Treatment of
Substance Use Disorders
Chapter 7. The Therapeutic Use of Psychedelics
in the Treatment of Psycho-Existential Distress in Palliative and
End-of-Life Care
Chapter 8. Psychedelic Treatment for Emerging
Indications: Eating Disorders, Autism, and Chronic Pain
Management
Part III: Considerations for Implementing Psychedelic
Treatment
Chapter 9. Psychedelics and Well-Being: Enhancements
and Risks
Chapter 10. The Psychedelic Therapy Treatment
Process
Chapter 11. The Future of Psychedelics in Psychiatry
Part I: Context, History, and
Biological Underpinnings of Psychedelic Treatment
Chapter 1.
Psychedelic Research and Treatment: Brief History of a Key
Pioneers
Chapter 2. Pharmacological and Neurobiological Mechanisms of
Action of Psychedelic substances
Part II: Illness Targets for
Psychedelic Research and Treatment
Chapter 3. The Illness
Targets: Mood Disorders and Suicide
Chapter 4. MDMA-Assisted Therapy for
Treatment of PTSD
Chapter 5. Psychedelic Treatment of OCD and Anxiety
Disorders: Early Work
Chapter 6. Psychedelics in the Treatment of
Substance Use Disorders
Chapter 7. The Therapeutic Use of Psychedelics
in the Treatment of Psycho-Existential Distress in Palliative and
End-of-Life Care
Chapter 8. Psychedelic Treatment for Emerging
Indications: Eating Disorders, Autism, and Chronic Pain
Management
Part III: Considerations for Implementing Psychedelic
Treatment
Chapter 9. Psychedelics and Well-Being: Enhancements
and Risks
Chapter 10. The Psychedelic Therapy Treatment
Process
Chapter 11. The Future of Psychedelics in Psychiatry